ePrints

Institutional Profile: The ATMP Manufacturing Community (amc)

Lookup NU author(s): Dr Lucy Foley, Dr Allan Osborne

Downloads

• Accepted version [.pdf]
• Accepted version [.pdf]

Abstract

This article describes the emergence, during 2011, of a community of best practice for the GMP manufacture of cellular therapies in the UK. The community originated in response to the anticipated demand for manufacturing capability as the UK increases its throughput of successful cell therapies. The community will catalyze the development of robust manufacturing processes essential to establishing the cell therapy industry in the UK. The Advanced Therapy Medicinal Product (ATMP) Manufacturing Community (amc) was formed in September 2010 as a community of best practice for cell therapy manufacturing in the UK. During 2011, the amc held three technical meetings, established an online presence via a website, Twitter and LinkedIn and now has 191 members. The amc aims to share nonconfidential information, develop best practice, inform and influence. The amc is also well placed to showcase UK GMP cell therapy manufacturing capability, which is currently well distributed and mostly focused on small-scale manufacture for clinical trials. The amc welcomes and encourages anyone with an interest in cell therapy manufacture to join.

Publication metadata

Author(s): Foley L, Callens S, Osborne A

Publication type: Article

Publication status: Published

Journal: Regenerative Medicine

Year: 2012

Volume: 7

Issue: 3

Pages: 285-289

Print publication date: 01/05/2012

Date deposited: 07/08/2012

ISSN (print): 1746-0751

ISSN (electronic): 1746-076X

Publisher: Future Medicine Ltd.

URL: http://dx.doi.org/10.2217/rme.12.9

DOI: 10.2217/rme.12.9

Altmetrics

Share